Unveiling of the eighth "Wuxi apptec prize for biochemical research"

Winner of outstanding achievement award of the 8th Pharmaceutical Research Award: Qiao Jie, Dean of the Third Hospital of Peking University, researcher of Shanghai Pharmaceutical Research Institute of Chinese Academy of Sciences, Wu Beili, vice president of Beijing Tiantan Hospital Affiliated to Capital Medical University, Wang Yongjun, Scholar Award of the 8th Pharmaceutical Research Award: Dong mengqiu, researcher of Beijing Institute of Life Sciences Yu Shuli, researcher of Shanghai Institute of organic chemistry, Chinese Academy of Sciences, special researcher of School of chemistry and molecular engineering, Peking University, Chen Xing, Professor of Department of chemistry, Tsinghua University, Li Jinghong, Dean and special professor of School of medicine, Fudan University, Zhu Yizhun, researcher of Shanghai Institute of medicine, Chinese Academy of Sciences, Yang Caiguang, Professor of Xiamen college of life sciences, Lin Tianwei Professor Hou tingjun, School of pharmacy, Zhejiang University, Professor Zhong Hongying, School of chemistry, Huazhong Normal University, Professor of Cardiovascular Research Institute, Peking University, Professor Liu Guoqing, Professor of State Key Laboratory of Biotherapy, Sichuan University, Professor Yang Li, Professor of School of life sciences, Tsinghua University, Professor Wang Xinquan, vice president and professor of internal medicine, people's Hospital, Peking University, Professor Chen Hong, School of pharmacy, Shanghai Jiaotong University, Professor Zhou Huchen Sun Tiansheng, vice president of Beijing Military General Hospital and director of the Institute of orthopaedic trauma "By 2020, about $259 billion worth of drugs will face the patent cliff, and the rising cost and difficulty of development will be the common problems faced by the global new drug research and development If we can play a key role in this, we will be able to The period will seize the opportunity, and it will be possible to truly achieve a breakthrough from a pharmaceutical power to a pharmaceutical power " How to achieve a breakthrough in innovation and R & D has become the most important topic in the pharmaceutical industry of China, which mainly focuses on the management of APIs and generic drugs However, Chinese enterprises participating in global innovative drug research and development through outsourcing in the early stage not only accumulate technical capabilities and intellectual capital, but also are familiar with international management and operation mode, which has become an important engine for Chinese biomedical industry to get rid of the long-term low-end situation in the industrial chain Chairman Li Ge, who returned to China in 2000 and founded Wuxi Pharmaceutical Co., Ltd and built it into the largest biomedical R & D platform company in Asia, said: "China is facing the best opportunity for the development of the pharmaceutical market Under the condition that policy, talent and investment are all the best in history, through an open platform to flexibly allocate technology, capabilities and resources, so that individuals and enterprises, scientists and entrepreneurs, traditional enterprises and emerging biological companies can obtain services covering the whole process of pharmaceutical research and development, which will effectively promote the reform and innovation of China's biomedical industry as a whole " To overcome two "10s": the cost of pharmaceutical research and development has been rising since the platform was built There have been two "10s" in the industry One is that most new drug research and development cycles are more than 10 years long, and the other is that the cost of new drug research and development is at least $1 billion The vast majority of international pharmaceutical companies choose pharmaceutical R & D enterprises represented by Wuxi pharmaceutical as their partners, which also makes more and more pharmaceutical giants and biomedical companies feel the great value How to improve the efficiency of R & D not only by reducing the cost of personnel? New R & D concepts and models are quietly changing the global pattern of biomedical R & D According to Dr Li Ge, the biggest change in pharmaceutical R & D is that it has changed from an isolated and closed R & D system to an open and networked R & D system, with a large number of external capabilities and technologies The R & D service platform is the most dynamic track Every entrepreneur and innovator is a relay runner of different sites From research, development and market, each runner is the best one We have effectively completed the marathon of new drug research and development It's not hard to imagine the chance of finishing a marathon in a relay run, which is much bigger than a runner running alone Two "wealth creation stories": the platform realizes the dream of drug R & D from Silicon Valley in the United States to Pudong in Shanghai Dr Yang Qing, chief operating officer of Wuxi Pharmaceutical Co., Ltd., who has been engaged in R & D in many famous pharmaceutical enterprises in the world, tells two customer cases of Wuxi Pharmaceutical Co., Ltd., showing the wealth creation ability of the biomedical industry One of them is an entrepreneurial team with only two full-time employees and one half-time employees in Pennsylvania They made very important experimental results of innovative drugs through the platform of Wuxi apptec within 18 months, and were acquired by another biotechnology company in the United States with 140 million US dollars Another small American company asked Wuxi to complete the synthesis of an anti hepatitis C compound, which was eventually acquired for $11 billion The new anti hepatitis C drug was later qualified as a "breakthrough drug" by the US FDA, and its sales volume exceeded 6 billion US dollars within six months after it was approved for listing It can be said that it is one of the largest blockbuster drugs in the global pharmaceutical industry From these two cases, it can be seen that pharmaceutical R & D is no longer the patent of large companies, but also confirms that the open technology and capability platform is a huge driving force for pharmaceutical R & D innovation and a subversion of traditional pharmaceutical R & D mode However, yaomingkant, who began to think about platform ten years ago, was not optimistic about the concept of "open platform" at that time, because "no one has done this" Li Ge, chairman of the board of directors, is very pleased with the achievements of innovation and adherence to the platform concept At present, Wuxi apptec has become the most recognized open platform company with the greatest pharmaceutical R & D strength in the world It also carries thousands of projects at home and abroad, including the whole process from research and exploration to commercialized production Small customers are as small as a company with only one employee, and large customers include the top ten multinational pharmaceutical giants in the world Among them, the R & D cooperation with Chinese pharmaceutical companies is going deep in an all-round way Enter Dr Li Ge said that "Chinese patients should enjoy the same high-level drug treatment means as Western patients" He hoped that the open R & D platform of Wuxi apptec would become a solid track to carry out the relay of Chinese pharmaceutical R & D, help anyone and any company to realize the dream and success of pharmaceutical R & D, and finally enable the Chinese people to really "use, and also It can afford the most advanced and effective new medicine in the world The group photo of the awardees and all the winners of the "Wuxi apptec biochemical research award" was established by the world's leading pharmaceutical, biotechnology and medical device R & D platform company, Wuxi apptec, with the approval of the Ministry of science and technology of the people's Republic of China Since its establishment in 2007, 128 scientists have won awards (8 of them have been selected as academicians of Chinese Academy of Sciences and Chinese Academy of Engineering), which has played an important role in promoting scientific research innovation and industrial development in related fields in China It is reported that from next year, the total amount of bonus will be increased from 2 million yuan to 3 million yuan, and two award fields of "genomics" and "bioinformatics" will be added.